Nivolumab and ipilimumab, two ICIs that target CTLA-4 and PD-1, induce T cell activation and cause tumor cells death by binding to B7 ligands CD80 and CD86 expressed on antigen-presenting cells (APCs) and PD-L1 on either tumor cells or APCs, respectively [10]. Here, CD80 is linked to neoplasm.